retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Retatrutide, an Amazing Future for Retatrutide Week by Week: Weight

The evolving landscape of semaglutide compounding The legal status of compounded semaglutide has shifted dramatically, and BPI Labs sits at the center of these changes

The FDA's Pharmacy Compounding Advisory Committee has been slated for an upcoming discussion on whether certain peptides from compounding pharmacies should be cleared for use, signaling a potential reversal of a 2023 decision by the agency, as Fierce Pharma reports

This means that patients taking levothyroxine for hypothyroidism or other thyroid medications can typically use semaglutide without loss of thyroid treatment benefit, provided proper dosing timing and monitoring are maintained

The reports of increased residual gastric content after long-term treatment with GLP-1 analogues emphasize that the effect on gastric emptying is sustained, even though that it does normally not pose a risk for postoperative respiratory complications [20]

Contact us at [email protected] if you see an error.